Shuangcheng Pharmaceutical disclosed its earnings forecast, expecting net profit attributable to shareholders of 10 million to 15 million yuan in the first half of 2026, compared with a loss of 18.4666 million yuan in the same period last year, turning from loss to profit year-on-year. Deducted non-recurring net profit is expected to be 7.5 million to 11 million yuan, compared with a loss of 21.0158 million yuan in the same period last year. Basic earnings per share are expected to be 0.0241 yuan to 0.0362 yuan. The company stated that the change in performance is mainly due to the orderly export business of its paclitaxel for injection (albumin-bound) product, with steady sales progress to US customers. The product obtained US marketing approval in May last year, and the sales period achievable in the same period last year was relatively short, leading to year-on-year revenue growth in the current period.
Hainan Shuangcheng PharmaceutExpects to turn profitable due to growing export sales of paclitaxel for injection (albumin-bound) to US customers.